Duke Picked for Hepatitis C Trials

The Duke Clinical Research Institute has been selected to run tests for a potential Hepatitis C cure. Benitec Biopharma Ltd., based in Sydney, Australia, is developing a drug to cure Hepatitis C and chose DCRI to run its Phase 1 and Phase 2 trials, the first in-human tests. Benitec has dubbed the drug TT-034.